356 related articles for article (PubMed ID: 24440599)
1. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
[TBL] [Abstract][Full Text] [Related]
2. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
4. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract][Full Text] [Related]
5. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
[TBL] [Abstract][Full Text] [Related]
6. Mir142 loss unlocks IDH2
Marshall A; Kasturiarachchi J; Datta P; Guo Y; Deltcheva E; James C; Brown J; May G; Anandagoda N; Jackson I; Howard JK; Ghazaly E; Brooks S; Khwaja A; Araki M; Araki K; Linch D; Lord GM; Enver T; Nimmo R
Sci Rep; 2020 Nov; 10(1):19390. PubMed ID: 33173219
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
8. [IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
Ogawara Y; Kitabayashi I
Rinsho Ketsueki; 2015 Aug; 56(8):1045-52. PubMed ID: 26345565
[TBL] [Abstract][Full Text] [Related]
9. Transgenic IDH2
Wang D; Zheng L; Cheng BYL; Sin CF; Li R; Tsui SP; Yi X; Ma ACH; He BL; Leung AYH; Sun X
Oncogene; 2023 Apr; 42(16):1272-1281. PubMed ID: 36739363
[TBL] [Abstract][Full Text] [Related]
10.
Trissal MC; Wong TN; Yao JC; Ramaswamy R; Kuo I; Baty J; Sun Y; Jih G; Parikh N; Berrien-Elliott MM; Fehniger TA; Ley TJ; Maillard I; Reddy PR; Link DC
Cancer Res; 2018 Jul; 78(13):3510-3521. PubMed ID: 29724719
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
12. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
13. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
14. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
[TBL] [Abstract][Full Text] [Related]
15. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
[TBL] [Abstract][Full Text] [Related]
16. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
[TBL] [Abstract][Full Text] [Related]
19. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]